An Overview of adenosine A2A receptor antagonists in Parkinson's disease

International Review of Neurobiology

Volumn 119, Issue , 2014, Pages 71-86

  Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trial; Dyskinesia; Neuroprotection; Nonmotor symptoms; Parkinson's disease

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; ISTRADEFYLLINE; LEVODOPA; PRELADENANT; ST 1535; TOZADENANT; UNCLASSIFIED DRUG; VIPADENANT; ADENOSINE A2 RECEPTOR ANTAGONIST;

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; ANIMAL;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE;

EID: 84906724483     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801022-8.00003-9     Document Type: Chapter

References (66)

1. Abbruzzese G., Barone P., Bonuccelli U., Lopiano L., Antonini A. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: Efficacy, safety and patient selection. Functional Neurology 2012, 27:147-154.
2. AlDakheel A., Kalia L.V., Lang A.E. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 2014, 11:6-23.
3. Antonini A., Ursino G., Calandrella D., Bernardi L., Plebani M. Continuous dopaminergic delivery in Parkinson's disease. Journal of Neurology 2010, 257:S305-S308.
4. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology 2003, 184:285-294.
5. 2A receptors in the brain. Synapse 2008, 62:671-681.
6. Brotchie J., Jenner P. New approaches to therapy. International Review of Neurobiology 2011, 98:123-150.
7. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain: A Journal of Neurology 2004, 127:1075-1084.
8. Chaudhuri K.R., Odin P., Antonini A., Martinez-Martin P. Parkinson's disease: The non-motor issues. Parkinsonism & Related Disorders 2011, 17:717-723.
9. 2A adenosine receptor inactivation in a model of Parkinson's disease. Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2001, 21:RC143.
10. 2A receptors and depression. Neurology 2003, 61:S82-S87.
11. 2A receptor knockout mice. British Journal of Pharmacology 2001, 134:68-77.
12. Factor S.A., Wolski K., Togasaki D.M., Huyck S., Cantillon M., Ho T.W., et al. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society 2013, 28:817-820.
13. Fenu S., Morelli M. Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: A different role of D1 and D2 receptors. European Journal of Neuroscience 1998, 10:1878-1884.
14. Fox S.H., Brotchie J.M., Lang A.E. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurology 2008, 7:927-938.
15. Fredholm B.B., Battig K., Holmen J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological Reviews 1999, 51:83-133.
16. 2A receptor antagonist in MPTP-treated monkeys. Neurology 1999, 52:1673-1677.
17. Guridi J., Gonzalez-Redondo R., Obeso J.A. Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease. Parkinson's Disease 2012, 2012:943159.
18. Hauser R.A., Cantillon M., Pourcher E., Micheli F., Mok V., Onofrj M., et al. Preladenant in patients with Parkinson's disease and motor fluctuations: A phase 2, double-blind, randomised trial. Lancet Neurology 2011, 10:221-229.
19. Hauser R.A., Shulman L.M., Trugman J.M., Roberts J.W., Mori A., Ballerini R., et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Movement Disorders: Official Journal of the Movement Disorder Society 2008, 23:2177-2185.
20. Hauser R., Stocchi F., Rascol O., Huyck S., Ha X., Capece R., et al. Phase-3 clinical trials of adjunctive therapy with preladenant, an adenosine 2a antagonist, in patients with Parkinson's disease (P7.087). Neurology 2014, 82(10 Suppl.):P7.087.
21. 2A receptor antagonist, is active in primate models of movement disorders. Experimental Neurology 2010, 225:384-390.
22. 2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. Journal of Pharmacology and Experimental Therapeutics 2009, 330:294-303.
23. 2A receptor blockade in experimental models of Parkinson's disease. Journal of Neurochemistry 2002, 80:262-270.
24. Johnston T.H., Brotchie J.M. Drugs in development for Parkinson's disease: An update. Current Opinion in Investigational Drugs 2006, 7:25-32.
25. 2A receptor gene disruption protects in an alpha-synuclein model of Parkinson's disease. Annals of Neurology 2012, 71:278-282.
26. 2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology 2013, 230:345-352.
27. 2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Annals of Neurology 1998, 43:507-513.
28. 2A antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Experimental Neurology 2000, 162:321-327.
29. 2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 1998, 9:2857-2860.
30. 2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003, 61:S97-S100.
31. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. European Journal of Pharmacology 2000, 408:249-255.
32. 2A antagonists in experimental models. Advances in Neurology 1999, 80:121-123.
33. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Annals of Neurology 2008, 63:295-302.
34. 2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. Journal of Neurochemistry 2003, 84:1398-1410.
35. Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M.M., Chaudhuri K.R. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society 2011, 26:399-406. SNMSS Validation Group.
36. Mizuno Y., Hasegawa K., Kondo T., Kuno S., Yamamoto M., Japanese Istradefylline Study Group Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study. Movement Disorders: Official Journal of the Movement Disorder Society 2010, 25:1437-1443.
37. Mizuno Y., Kondo T., Japanese Istradefylline Study Group Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society 2013, 28:1138-1141.
38. 2A receptors and Parkinson's disease. Handbook of Experimental Pharmacology 2009, 193:589-615.
39. 2A antagonists. Neurology 2003, 61:S44-S48.
40. Obeso J.A., Rodriguez-Oroz M.C., Benitez-Temino B., Blesa F.J., Guridi J., Marin C., et al. Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society 2008, 23(Suppl. 3):S548-S559.
41. Palacios N., Gao X., McCullough M.L., Schwarzschild M.A., Shah R., Gapstur S., et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Movement Disorders: Official Journal of the Movement Disorder Society 2012, 27:1276-1282.
42. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Archives of Neurology 2005, 62:241-248.
43. Perez-Lloret S., Merello M. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: Istradefylline versus tozadenant. Expert Opinion on Pharmacotherapy 2014, 15:1097-1107.
44. Pierri M., Vaudano E., Sager T., Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005, 48:517-524.
45. 2A receptor antagonists for Parkinson's disease. Expert Opinion on Investigational Drugs 2009, 18:1619-1631.
46. 2A receptor antagonists in Parkinson's disease: Progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 2014, 28:455-474.
47. 2A receptor antagonists: Actions on Parkinson's disease models. European Journal of Pharmacology 2005, 512:157-164.
48. Postuma R.B., Lang A.E., Munhoz R.P., Charland K., Pelletier A., Moscovich M., et al. Caffeine for treatment of Parkinson disease: A randomized controlled trial. Neurology 2012, 79:651-658.
49. Pourcher E., Fernandez H.H., Stacy M., Mori A., Ballerini R., Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study. Parkinsonism & Related Disorders 2012, 18:178-184.
50. Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76:1811-1816.
51. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): A randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
52. Rektorova I., Aarsland D., Chaudhuri K.R., Strafella A.P. Nonmotor symptoms of Parkinson's disease. Parkinson's Disease 2011, 2011:351461.
53. 2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets. European Journal of Pharmacology 2006, 546:82-87.
54. 2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Research 2007, 1133:110-114.
55. 2A receptor antagonist for the potential treatment of parkinsonism and other disorders. IDrugs: The Investigational Drugs Journal 2010, 13:723-731.
56. 2A receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus. Journal of Physiology 2001, 532:423-434.
57. 2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus. British Journal of Pharmacology 2002, 136:296-302.
58. 2A receptors in rats. Neuroscience Letters 2003, 352:167-170.
59. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999, 147:90-95.
60. Stacy M., Silver D., Mendis T., Sutton J., Mori A., Chaikin P., et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008, 70:2233-2240.
61. 2A receptor antagonist ST1535: Acute and subchronic studies in rats. European Journal of Pharmacology 2007, 566:94-102.
62. 2A-receptor antagonist istradefylline enhances the motor response of l-DOPA without worsening dyskinesia in MPTP-treated common marmosets. Journal of Pharmacological Sciences 2014, 124:480-485.
63. Xiao D., Cassin J.J., Healy B., Burdett T.C., Chen J.F., Fredholm B.B., et al. Deletion of adenosine A(1) or A((2)A) receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Research 2011, 1367:310-318.
64. 2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacology, Biochemistry, and Behavior 2013, 114-115:23-30.
65. Yamada K., Kobayashi M., Shiozaki S., Ohta T., Mori A., Jenner P., et al. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology 2014, 231(14):2839-2849.
66. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Annals of Neurology 2008, 63:338-346.